Becky Mccall

MUNICH — Direct oral anticoagulant (DOAC) therapy reduced the risk for adverse clinical events by 69% compared with no anticoagulation in patients

Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.

MUNICH — Adding the investigational factor XIa inhibitor milvexian to standard antiplatelet therapy did not reduce cardiovascular (CV) events after

MUNICH — Atorvastatin reduced the risk of major cardiovascular (CV) events, predominantly nonfatal events, by 30% compared with placebo in adults

Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.

The 1-hour troponin pathway was safely implemented in a real-world study but did not impact workflow in busy emergency departments.

MUNICH — Switching from a 3-hour to a 1-hour high-sensitivity cardiac troponin pathway for patients with suspected myocardial infarction (MI) was

Edoxaban reduced ischemic stroke after intracranial hemorrhage in patients with AF, but excess hemorrhagic stroke and major bleeding offset the benefit.

MUNICH — Edoxaban did not reduce the overall risk of stroke or systemic embolism in patients with atrial fibrillation (AF) who had previously

Transcatheter tricuspid valve repair added to medical therapy reduced clinical events in patients with severe tricuspid regurgitation, with marked reduction in HF hospitalization.